Steven W Johnson1,2, Shannon V Brown1, David H Priest3,4. 1. Department of Pharmacy Practice, Campbell University College of Pharmacy and Health Science, Buies Creek, North Carolina, USA. 2. Department of Pharmacy, Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, USA. 3. Novant Health Institute for Safety and Quality, Winston-Salem, North Carolina, USA. 4. Novant Health Infectious Disease Specialists, Winston-Salem, North Carolina, USA.
Abstract
BACKGROUND: Limited retrospective data suggest prophylactic oral vancomycin may prevent Clostridioides difficile infection (CDI). We sought to evaluate the effectiveness of oral vancomycin for the prevention of healthcare facility-onset CDI (HCFO-CDI) in targeted patients. METHODS: We conducted a randomized, prospective, open-label study at Novant Health Forsyth Medical Center in Winston-Salem, North Carolina, between October 2018 and April 2019. Included patients were randomized 1:1 to either oral vancomycin (dosed at 125 mg once daily while receiving systemic antibiotics and continued for 5 days postcompletion of systemic antibiotics [OVP]) or no prophylaxis. The primary endpoint was incidence of HCFO-CDI. Secondary endpoints included incidence of community-onset healthcare facility-associated CDI (CO-HCFA-CDI), incidence of vancomycin-resistant Enterococci (VRE) colonization after receiving OVP, adverse effects, and cost of OVP. RESULTS:A total of 100 patients were evaluated, 50 patients in each arm. Baseline and hospitalization characteristics were similar, except antibiotic exposure. No events of HCFO-CDI were noted in the OVP group compared with 6 (12%) in the no-prophylaxis group (P = .03). CO-HCFA-CDI was identified in 2 patients who were previously diagnosed with HCFO-CDI. No patients developed new VRE colonization, with only 1 patient reporting mild gastrointestinal side effects to OVP. A total of 600 doses of OVP were given during the study, with each patient receiving an average of 12 doses. Total acquisition cost of OVP was $1302, $26.04 per patient. CONCLUSION:OVP appears to protect against HCFO-CDI during in-patient stay in targeted patients during systemic antibiotic exposure. Further prospective investigation is warranted.
RCT Entities:
BACKGROUND: Limited retrospective data suggest prophylactic oral vancomycin may prevent Clostridioides difficileinfection (CDI). We sought to evaluate the effectiveness of oral vancomycin for the prevention of healthcare facility-onset CDI (HCFO-CDI) in targeted patients. METHODS: We conducted a randomized, prospective, open-label study at Novant Health Forsyth Medical Center in Winston-Salem, North Carolina, between October 2018 and April 2019. Included patients were randomized 1:1 to either oral vancomycin (dosed at 125 mg once daily while receiving systemic antibiotics and continued for 5 days postcompletion of systemic antibiotics [OVP]) or no prophylaxis. The primary endpoint was incidence of HCFO-CDI. Secondary endpoints included incidence of community-onset healthcare facility-associated CDI (CO-HCFA-CDI), incidence of vancomycin-resistant Enterococci (VRE) colonization after receiving OVP, adverse effects, and cost of OVP. RESULTS: A total of 100 patients were evaluated, 50 patients in each arm. Baseline and hospitalization characteristics were similar, except antibiotic exposure. No events of HCFO-CDI were noted in the OVP group compared with 6 (12%) in the no-prophylaxis group (P = .03). CO-HCFA-CDI was identified in 2 patients who were previously diagnosed with HCFO-CDI. No patients developed new VRE colonization, with only 1 patient reporting mild gastrointestinal side effects to OVP. A total of 600 doses of OVP were given during the study, with each patient receiving an average of 12 doses. Total acquisition cost of OVP was $1302, $26.04 per patient. CONCLUSION: OVP appears to protect against HCFO-CDI during in-patient stay in targeted patients during systemic antibiotic exposure. Further prospective investigation is warranted.
Authors: Alice Y Guh; Sarah H Yi; James Baggs; Lisa Winston; Erin Parker; Helen Johnston; Elizabeth Basiliere; Danyel Olson; Scott K Fridkin; Nirja Mehta; Lucy Wilson; Rebecca Perlmutter; Stacy M Holzbauer; Paige D'Heilly; Erin C Phipps; Kristina G Flores; Ghinwa K Dumyati; Trupti Hatwar; Rebecca Pierce; Valerie L S Ocampo; Christopher D Wilson; Jasmine J Watkins; Lauren Korhonen; Ashley Paulick; Michelle Adamczyk; Dale N Gerding; Sujan C Reddy Journal: Open Forum Infect Dis Date: 2022-08-17 Impact factor: 4.423
Authors: Ilan S Schwartz; Todd McCarty; Laila E Woc-Colburn; Boghuma K Titanji; James B Cutrell; Nicolas W Cortes-Penfield Journal: Clin Infect Dis Date: 2022-05-15 Impact factor: 20.999
Authors: Max W Adelman; Michael H Woodworth; Virginia O Shaffer; Greg S Martin; Colleen S Kraft Journal: Crit Care Med Date: 2021-01-01 Impact factor: 9.296